Jamey Weichert, co-founder and chief scientific officer of Cellectar Biosciences, will be leaving the company on July 15, Cellectar said in a document filed Thursday with the SEC. Madison, WI-based Cellectar (NASDAQ: [[ticker:CLRB]]) is seeking to commercialize cancer drugs and imaging agents that would be delivered to their targets by special compounds called phospholipid ethers. Weichert, who is also a radiology professor at the University of Wisconsin-Madison, tendered his resignation from Cellectar on Friday, according to the SEC document. Shares in Cellectar ended the trading day down 1.2 percent, and as of this writing were down more than 7 percent in after-hours trading.
